|
Arizona researchers are playing a key role in the search for new ways to identify CTE before death. In a study released online in the New England Journal of Medicine, a cross-national team, including local researchers from Arizona State University, Banner Alzheimer’s Institute, the Mayo Clinic College of Medicine, and Boston University have brought us a step closer to diagnosing CTE in living, former NFL players.
TUCSON, Ariz., April 9, 2019 — Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium announces U.S. Food and Drug Administration (FDA) qualification of two new clinical outcome assessment tools: the Asthma Daytime Symptom Diary(ADSD) and the Asthma Nighttime Symptom Diary (ANSD). The qualification of the ADSD and the ANSD represents a major milestone for the PRO Consortium and specifically for the Asthma Working Group. It is the culmination of a multi-year collaboration between FDA’s Center for Drug Evaluation and Research (CDER) and the PRO Consortium.
Washington, D.C. (April 3, 2019) – Senator Kyrsten Sinema was recognized today by the Biotechnology Innovation Organization (BIO) for her leadership as an Innovator in Biotechnology. Senator Sinema received the award in conjunction with today’s BIO Legislative Day Fly-In.
While antibiotic resistance is on the rise, pharmaceutical companies are making fewer and fewer new antibiotics. UA immunobiologist Michael Johnson says this trend is in urgent need of reversal and believes copper might just be the key.
C-Path President and CEO Martha Brumfield, PhD, and C-Path Board Director Alastair J. Wood, MD, FRCP, have both been selected to the serve on the National Academy Consensus Committee examining Mutual Recognition Agreements in the Regulation of Medicines under The National Academies of Sciences, Engineering and Medicine. Dr. Wood will serve as chair.
The Flinn Foundation and The Arizona Republic have entered into a grant-based partnership that will enable the state’s largest media platform to pursue a multimedia initiative to deepen public understanding of the biosciences in Arizona, including research, industry development, and clinical advances. |
